Equity Details
Price & Market Data
Price: $31.54
Daily Change: +$0.65 / 2.06%
Daily Range: $30.45 - $31.88
Market Cap: $492,521,920
Daily Volume: 95,873
Performance Metrics
1 Week: 8.98%
1 Month: 63.59%
3 Months: 85.53%
6 Months: 17.91%
1 Year: 78.19%
YTD: 53.11%
About Neurogene Inc. (NGNE)
Stock insights for Neurogene Inc. (NGNE). Price: 31.54, daily change: +$0.65 / 2.06%. Market cap: 492,521,920. Performance 3-month, 6-month, 1-year.
Company Details
Employees: 131
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.